Alopecia areata (AA) is a T-cell-mediated autoimmune disease characterized by nonscarring hair loss on the scalp and body. This is a retrospective single-centre study, performed at the trichology outpatient clinic of the University Federico II of Naples from January 2023 to January 2024, on a case series of 15 adolescent patients (12–17 years old) with severe AA who were treated for at least 24 weeks with off-label use of upadacitinib. Treatment with upadacitinib has a promising efficacy and safety profile in the treatment of severe AA in adolescent patients.
No takes yet. Share an insight, caveat, or question.
Picone et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: